Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

CD137 antibody

TNFRSF9 Reactivity: Human, Cynomolgus ELISA, FACS Host: Rat Monoclonal JG1-6A unconjugated
Catalog No. ABIN2478424
  • Target See all CD137 (TNFRSF9) Antibodies
    CD137 (TNFRSF9) (Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))
    Reactivity
    • 100
    • 40
    • 26
    • 8
    • 4
    • 1
    • 1
    Human, Cynomolgus
    Host
    • 52
    • 37
    • 13
    • 12
    • 2
    Rat
    Clonality
    • 56
    • 55
    • 3
    Monoclonal
    Conjugate
    • 63
    • 12
    • 7
    • 6
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This CD137 antibody is un-conjugated
    Application
    • 67
    • 59
    • 55
    • 13
    • 12
    • 11
    • 10
    • 6
    • 5
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Flow Cytometry (FACS)
    Cross-Reactivity
    Cynomolgus
    Characteristics
    Purified IgG
    Purification
    Purified
    Immunogen
    Recombinant human CD137-Fc
    Clone
    JG1-6A
    Isotype
    IgG2a
    Top Product
    Discover our top product TNFRSF9 Primary Antibody
  • Application Notes
    Optimal working dilution should be determined by the investigator.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1.0 mg/mL
  • Cannons, Lau, Ghumman, DeBenedette, Yagita, Okumura, Watts: "4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 167, Issue 3, pp. 1313-24, (2001) (PubMed).

  • Target
    CD137 (TNFRSF9) (Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))
    Alternative Name
    CD137 (TNFRSF9 Products)
    Background
    Synonyms: 4-1BB LIGAND RECEPTOR
    Gene ID
    3604
    UniProt
    Q07011
    Pathways
    Cancer Immune Checkpoints
You are here:
Support